Department of Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy.
Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Clin Exp Dermatol. 2020 Oct;45(7):888-890. doi: 10.1111/ced.14260. Epub 2020 May 24.
Atopic dermatitis (AD) is a common inflammatory skin disease with high prevalence in both children (15-30%) and adults (2-10%), but limited data are available for older people. Elderly patients form a challenging group, as multiple comorbidities, associated polypharmacy and failures with previous treatments are common. We performed a retrospective observational study on elderly (≥ 65 years) patients treated with dupilumab, monoclonal antibody to the shared alpha subunit of the interleukin-4 and -13 receptor approved for the treatment of moderate-to-severe AD in adults.
特应性皮炎（AD）是一种常见的炎症性皮肤病，在儿童（15-30%）和成人（2-10%）中均有较高的发病率，但老年人的数据有限。老年患者是一个具有挑战性的群体，因为他们常伴有多种合并症、相关的多种药物治疗以及以前治疗的失败。我们对接受度普利尤单抗治疗的老年（≥65 岁）患者进行了回顾性观察性研究，度普利尤单抗是一种针对白细胞介素-4 和 -13 受体共用的α亚单位的单克隆抗体，已被批准用于治疗成人中重度 AD。
